Prothrombotic changes in diabetes mellitus

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 5, 2013, Pages 477-488

  Morel, Olivier ^a   Jesel, Laurence ^a   Abbas, Malak ^b   Morel, Nicolas ^c  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b LEBANESE UNIVERSITY   (Lebanon)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

angiogenesis; endothelial damage; leukocyte activation; microparticles; myocardial infarction; platelet stimulation; thrombosis; tissue factor

Indexed keywords

ATORVASTATIN; GLIBENCLAMIDE; HEMOGLOBIN A1C; ICOSAPENTAENOIC ACID; INSULIN; MIGLITOL; PIOGLITAZONE; PITAVASTATIN;

ANTICOAGULATION; ARTICLE; ATHERMATOUS PLAQUE; CARDIOVASCULAR DISEASE; CELL AGING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ACTIVATION; MOLECULAR MECHANICS; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOGENICITY; THROMBOPHILIA; THROMBOSIS; VASCULAR DISEASE;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PLATELET ACTIVATION; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84879114327     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1343888     Document Type: Article

References (103)

1. Haffner S. M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med: 1998; 339 4 229 234
2. Holst A. G., Jensen G., Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation: 2010; 121 17 1896 1903
3. Wattanakit K., Lutsey P. L., Bell E. J., et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost: 2012; 108 3 508 515
4. Vazzana N., Ranalli P., Cuccurullo C., Davì G. Diabetes mellitus and thrombosis. Thromb Res: 2012; 129 3 371 377
5. Orasanu G., Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol: 2009; 53 (5, Suppl): S35 S42
6. Morel O., Kessler L., Ohlmann P., Bareiss P. Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis: 2010; 212 2 367 376
7. Tschoepe D., Roesen P., Esser J., et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost: 1991; 17 4 433 438
8. Guthikonda S., Alviar C. L., Vaduganathan M., et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol: 2008; 52 9 743 749
9. Morel O., Hugel B., Jesel L., et al. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost: 2004; 91 2 345 353
10. Kakouros N., Rade J. J., Kourliouros A., Resar J. R. Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol: 2011; 2011 742719
11. Hernández Vera R., Vilahur G., Ferrer-Lorente R., Peña E., Badimon L. Platelets derived from the bone marrow of diabetic animals show dysregulated endoplasmic reticulum stress proteins that contribute to increased thrombosis. Arterioscler Thromb Vasc Biol: 2012; 32 9 2141 2148
12. Santilli F., Formoso G., Sbraccia P., et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost: 2010; 8 4 828 837
13. Yngen M., Ostenson C. G., Li N., Hjemdahl P., Wallén N. H. Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus. Blood Coagul Fibrinolysis: 2001; 12 2 109 116
14. Vaidyula V. R., Rao A. K., Mozzoli M., Homko C., Cheung P., Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes: 2006; 55 1 202 208
15. Randriamboavonjy V., Pistrosch F., Bölck B., et al. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation: 2008; 117 1 52 60
16. Morel O., Toti F., Jesel L., Freyssinet J. M. Mechanisms of microparticle generation: on the trail of the mitochondrion! Semin Thromb Hemost: 2010; 36 8 833 844
17. Morel O., Jesel L., Freyssinet J. M., Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol: 2011; 31 1 15 26
18. Assert R., Scherk G., Bumbure A., Pirags V., Schatz H., Pfeiffer A. F. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia: 2001; 44 2 188 195
19. De Cristofaro R., Rocca B., Vitacolonna E., et al. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost: 2003; 1 2 250 256
20. Chappey O., Dosquet C., Wautier M. P., Wautier J. L. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest: 1997; 27 2 97 108
21. Thomas G., Skrinska V., Lucas F. V., Schumacher O. P. Platelet glutathione and thromboxane synthesis in diabetes. Diabetes: 1985; 34 10 951 954
22. Davì G., Catalano I., Averna M., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med: 1990; 322 25 1769 1774
23. Queen L. R., Ji Y., Goubareva I., Ferro A. Nitric oxide generation mediated by beta-adrenoceptors is impaired in platelets from patients with Type 2 diabetes mellitus. Diabetologia: 2003; 46 11 1474 1482
24. Ferreira I. A., Eybrechts K. L., Mocking A. I., Kroner C., Akkerman J. W. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem: 2004; 279 5 3254 3264
25. Ferreira I. A., Mocking A. I., Feijge M. A., et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol: 2006; 26 2 417 422
26. Falcon C., Pfliegler G., Deckmyn H., Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun: 1988; 157 3 1190 1196
27. Singla A., Antonino M. J., Bliden K. P., Tantry U. S., Gurbel P. A. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J: 2009; 158 5 e1 e6
28. Geisler T., Anders N., Paterok M., et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care: 2007; 30 2 372 374
29. Vivas D., García-Rubira J. C., Bernardo E., et al. Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudoo"). Heart: 2011; 97 10 803 809
30. Angiolillo D. J., Bernardo E., Ramírez C., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol: 2006; 48 2 298 304
31. Morel O., El Ghannudi S., Hess S., et al. The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. Thromb Haemost: 2012; 108 2 338 348
32. Gaborit B., Frère C., Cuisset T., Alessi M. C., Dutour A. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. J Thromb Haemost: 2009; 7 11 1939 1941
33. Mangiacapra F., Patti G., Peace A., et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol: 2010; 106 5 619 623
34. Erlinge D., Varenhorst C., Braun O. O., et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol: 2008; 52 24 1968 1977
35. Geisler T., Mueller K., Aichele S., et al. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol: 2010; 99 11 743 752
36. Sanchez P. L., Morinigo J. L., Pabon P., et al. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. Heart: 2004; 90 3 264 269
37. Vaidyula V. R., Boden G., Rao A. K. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets: 2006; 17 8 577 585
38. Sage A. T., Holtby-Ottenhof S., Shi Y., Damjanovic S., Sharma A. M., Werstuck G. H. Metabolic syndrome and acute hyperglycemia are associated with endoplasmic reticulum stress in human mononuclear cells. Obesity (Silver Spring): 2012; 20 4 748 755
39. Dasu M. R., Devaraj S., Jialal I. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab: 2007; 293 1 E337 E346
40. Venugopal S. K., Devaraj S., Yang T., Jialal I. Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes: 2002; 51 10 3049 3054
41. Gawlowski T., Stratmann B., Stirban A. O., Negrean M., Tschoepe D. AGEs and methylglyoxal induce apoptosis and expression of Mac-1 on neutrophils resulting in platelet-neutrophil aggregation. Thromb Res: 2007; 121 1 117 126
42. Ling L., Shen Y., Wang K., et al. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization. PLoS ONE: 2012; 7 11 e50739
43. Moreno P. R., Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol: 2004; 44 12 2293 2300
44. Rubenstein D. A., Maria Z., Yin W. Glycated albumin modulates endothelial cell thrombogenic and inflammatory responses. J Diabetes Sci Tech: 2011; 5 3 703 713
45. Otsuka A., Azuma K., Iesaki T., et al. Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia: 2005; 48 12 2667 2674
46. Vogl-Willis C. A., Edwards I. J. High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol: 2004; 24 5 858 863
47. Moreno P. R., Murcia A. M., Palacios I. F., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation: 2000; 102 18 2180 2184
48. Burke A. P., Kolodgie F. D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol: 2004; 24 7 1266 1271
49. Tabas I., Seimon T., Arellano J., et al. The impact of insulin resistance on macrophage death pathways in advanced atherosclerosis. Novartis Found Symp: 2007; 286 99 109, discussion 109-112, 162-163, 196-203
50. Purushothaman K. R., Purushothaman M., Muntner P., et al. Inflammation, neovascularization and intra-plaque hemorrhage are associated with increased reparative collagen content: implication for plaque progression in diabetic atherosclerosis. Vasc Med: 2011; 16 2 103 108
51. Pandolfi A., De Filippis E. A. Chronic hyperglycemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications. Genes Nutr: 2007; 2 2 195 208
52. Olson F. J., Strömberg S., Hjelmgren O., Kjelldahl J., Fagerberg B., Bergström G. M. Increased vascularization of shoulder regions of carotid atherosclerotic plaques from patients with diabetes. J Vasc Surg: 2011; 54 5 1324 1331, e5
53. Moreno P. R., Purushothaman M., Purushothaman K. R. Plaque neovascularization: defense mechanisms, betrayal, or a war in progress. Ann N Y Acad Sci: 2012; 1254 7 17
54. Levy A. P., Purushothaman K. R., Levy N. S., et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res: 2007; 101 1 106 110
55. Osende J. I., Badimon J. J., Fuster V., et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol: 2001; 38 5 1307 1312
56. Davì G., Gennaro F., Spatola A., et al. Thrombin-antithrombin III complexes in type II diabetes mellitus. J Diabetes Complications: 1992; 6 1 7 11
57. Wasty F., Alavi M. Z., Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia: 1993; 36 4 316 322
58. Borcea V., Morcos M., Isermann B., et al. Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus. Vasa: 1999; 28 3 172 180
59. Fujiwara Y., Tagami S., Kawakami Y. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy. J Atheroscler Thromb: 1998; 5 1 21 28
60. Isermann B., Vinnikov I. A., Madhusudhan T., et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med: 2007; 13 11 1349 1358
61. Hernestål-Boman J., Norberg M., Jansson J. H., et al. Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study. Cardiovasc Diabetol: 2012; 11 152
62. Tripodi A., Branchi A., Chantarangkul V., et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis: 2011; 31 2 165 172
63. Tsimerman G., Roguin A., Bachar A., Melamed E., Brenner B., Aharon A. Involvement of microparticles in diabetic vascular complications. Thromb Haemost: 2011; 106 2 310 321
64. Jung K. H., Chu K., Lee S. T., et al. Risk of macrovascular complications in type 2 diabetes mellitus: endothelial microparticle profiles. Cerebrovasc Dis: 2011; 31 5 485 493
65. Bogdanov V. Y., Osterud B. Cardiovascular complications of diabetes mellitus: the tissue factor perspective. Thromb Res: 2010; 125 2 112 118
66. Ichikawa K., Yoshinari M., Iwase M., et al. Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients. Atherosclerosis: 1998; 136 2 281 287
67. Boden G., Vaidyula V. R., Homko C., Cheung P., Rao A. K. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab: 2007; 92 11 4352 4358
68. Morel O., Toti F., Hugel B., et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol: 2006; 26 12 2594 2604
69. Morel O., Pereira B., Averous G., et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis: 2009; 204 2 636 641
70. Falati S., Liu Q., Gross P., et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med: 2003; 197 11 1585 1598
71. Lacroix R., Dignat-George F. Microparticles: new protagonists in pericellular and intravascular proteolysis. Semin Thromb Hemost: 2013; 39 1 33 39
72. Lozito T. P., Tuan R. S. Endothelial cell microparticles act as centers of matrix metalloproteinsase-2 (MMP-2) activation and vascular matrix remodeling. J Cell Physiol: 2012; 227 2 534 549
73. Ettelaie C., Su S., Li C., Collier M. E. Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells. Microvasc Res: 2008; 76 3 152 160
74. Chahed S., Leroyer A. S., Benzerroug M., et al. Increased vitreous shedding of microparticles in proliferative diabetic retinopathy stimulates endothelial proliferation. Diabetes: 2010; 59 3 694 701
75. Steppich B. A., Braun S. L., Stein A., et al. Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. Thromb J: 2009; 7 11
76. Porto I., Biasucci L. M., De Maria G. L., et al. Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Eur Heart J: 2012; 33 23 2928 2938
77. Sinning J. M., Losch J., Walenta K., Böhm M., Nickenig G., Werner N. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J: 2011; 32 16 2034 2041
78. Nozaki T., Sugiyama S., Koga H., et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol: 2009; 54 7 601 608
79. Chen J., Chen S., Chen Y., et al. Circulating endothelial progenitor cells and cellular membrane microparticles in db/db diabetic mouse: possible implications in cerebral ischemic damage. Am J Physiol Endocrinol Metab: 2011; 301 1 E62 E71
80. Curtis A. M., Zhang L., Medenilla E., et al. Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population. Cytometry B Clin Cytom: 2010; 78 5 329 337
81. Chen Y., Feng B., Li X., Ni Y., Luo Y. Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes. J Clin Hypertens (Greenwich): 2012; 14 7 455 460
82. Pirro M., Schillaci G., Bagaglia F., et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis: 2008; 197 2 757 767
83. Feng B., Chen Y., Luo Y., Chen M., Li X., Ni Y. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis: 2010; 208 1 264 269
84. Koga H., Sugiyama S., Kugiyama K., et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol: 2005; 45 10 1622 1630
85. Huang P. H., Huang S. S., Chen Y. H., et al. Increased circulating CD31+/annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens: 2010; 28 8 1655 1665
86. Wiviott S. D., Braunwald E., Angiolillo D. J., et al. TRITON-TIMI 38 Investigators Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation: 2008; 118 16 1626 1636
87. James S., Angiolillo D. J., Cornel J. H., et al. PLATO Study Group Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J: 2010; 31 24 3006 3016
88. Wang T. H., Bhatt D. L., Fox K. A., et al. CHARISMA Investigators An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J: 2007; 28 18 2200 2207
89. Gerrits A. J., Koekman C. A., Yildirim C., Nieuwland R., Akkerman J. W. Insulin inhibits tissue factor expression in monocytes. J Thromb Haemost: 2009; 7 1 198 205
90. Henriksson C. E., Hellum M., Haug K. B., et al. Anticoagulant effects of an antidiabetic drug on monocytes in vitro. Thromb Res: 2011; 128 5 e100 e106
91. Nomura S., Omoto S., Yokoi T., et al. Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. Int J Gen Med: 2011; 4 539 545
92. Esposito K., Maiorino M. I., Di Palo C., et al. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes-a randomized controlled trial. Diabetes Obes Metab: 2011; 13 5 439 445
93. Tramontano A. F., O'Leary J., Black A. D., Muniyappa R., Cutaia M. V., El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun: 2004; 320 1 34 38
94. Sommeijer D. W., Joop K., Leyte A., Reitsma P. H., ten Cate H. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost: 2005; 3 6 1168 1171
95. Tehrani S., Mobarrez F., Antovic A., et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res: 2010; 126 3 e225 e231
96. Nomura S., Inami N., Shouzu A., et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets: 2009; 20 1 16 22
97. Koh K. K., Quon M. J., Han S. H., Ahn J. Y., Lee Y., Shin E. K. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis: 2007; 194 1 230 237
98. Diamant M., Tushuizen M. E., Abid-Hussein M. N., et al. Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. Thromb Haemost: 2008; 100 3 489 497
99. Morel O., Jesel L., Hugel B., et al. Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J Thromb Haemost: 2003; 1 1 171 177
100. Nomura S., Shouzu A., Omoto S., et al. Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes. J Atheroscler Thromb: 2009; 16 2 83 90
101. Morel O., Luca F., Grunebaum L., et al. Short-term very low-calorie diet in obese females improves the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished release of platelet and leukocyte-derived microparticles. Int J Obes (Lond): 2011; 35 12 1479 1486
102. Cheng V., Kashyap S. R., Schauer P. R., Kirwan J. P., McCrae K. R. Restoration of glycemic control in patients with type 2 diabetes mellitus after bariatric surgery is associated with reduction in microparticles. Surg Obes Relat Dis: 2011
103. Shimazu T., Inami N., Satoh D., et al. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients. J Thromb Thrombolysis: 2009; 28 4 429 435